Biotech BioNTech cooperates with Penn university on mRNA vaccinesGerman biotech BioNTech has signed an agreement with the University of Pennsylvania for the development of mRNA-based vaccine for 10 infectious disease indications, reported Frankfurter Allgemeine Zeitung (FAZ) on Tuesday (p33).
Last days for Stada sharesShares of German generic drugmaker Stada are likely to be delisted before the end of November, FAZ said on Wednesday (p25).
Promising Phase II results for GSK's tuberculosis vaccine candidateGlaxoSmithKline's vaccine candidate M72/AS01 prevented 54% of tuberculosis outbreaks in infected patients, according to Phase II results published in the New England Journal of Medicine (NEJM), Sueddeutsche Zeitung (SZ) reported on Monday (p14).
Israeli biotech develops HIV drug GammoraIsraeli biotech Zion Medical has published promising results for its HIV drug candidate Gammora, reports Die Welt on Friday (p20).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.